NVE (NVEC) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
3 Feb, 2026Executive summary
Revenue for Q1 FY2025 declined 23% year-over-year to $6.78 million, mainly due to a 24% drop in product sales, partially offset by a 28% increase in contract R&D revenue.
Net income decreased 7% year-over-year to $4.10 million, or $0.85 per diluted share, with higher gross margin and interest income partially offsetting lower revenue.
Gross margin improved to 86% from 77% year-over-year, driven by a more profitable product mix and higher direct sales.
Operating cash flow increased 16% to $5.9 million, supporting a $4.83 million dividend.
Comprehensive income was down just 1% due to unrealized gains on marketable securities.
Financial highlights
Product sales were $6.62 million, down from $8.70 million year-over-year; contract R&D revenue rose to $167,000 from $131,000.
Total revenue: $6.8 million for Q1 FY2025, down from $8.8 million in Q1 FY2024.
Cash and cash equivalents stood at $6.01 million as of June 30, 2024, down from $10.28 million at March 31, 2024.
Cash plus marketable securities rose to $53.2 million, even after dividend and $917,000 in CapEx.
Cash dividends paid: $1.00 per share, totaling $4.8 million in the quarter.
Outlook and guidance
Industry forecasts indicate recovery in calendar 2024 and strong growth in 2025.
Investments in wafer-level chip-scale packaging and increased fixed asset purchases expected to drive future revenue and margin improvement.
Defense business, including PUFs, expected to remain strong in the near term.
Future dividends will be funded by operating cash flow and maturing securities, subject to Board approval and business conditions.
Management expressed satisfaction with earnings performance despite industry challenges.
Latest events from NVE
- Q3 revenue up 23% to $6.22M, net income up 11%, and a $1.00 dividend declared.NVEC
Q3 20268 Jul 2026 - Director elections, executive pay, and auditor ratification headline the 2026 annual meeting.NVEC
Proxy filing22 Jun 2026 - Shareholders will vote on directors, executive pay, and auditor ratification at the 2026 meeting.NVEC
Proxy filing22 Jun 2026 - Leadership transitions and robust growth mark a year of expansion and innovation.NVEC
Proxy filing22 Jun 2026 - Board expansion, executive pay, and auditor ratification headline the August 2026 proxy.NVEC
Proxy filing22 Jun 2026 - Quarterly net income rose 27% year-over-year, driven by strong product sales and margin gains.NVEC
Q4 20267 May 2026 - Gross margin rose to 86% as R&D revenue surged and a $1.00 dividend was declared.NVEC
Q2 202519 Jan 2026 - Revenue and net income fell, but gross margin improved to 84% and a dividend was declared.NVEC
Q3 20259 Jan 2026 - Maintained strong earnings, expanded R&D, and appointed a new director with medical expertise.NVEC
Proxy Filing1 Dec 2025